Mylan NV (NASDAQ:MYL) was the target of a significant increase in short interest in the month of August. As of August 31st, there was short interest totalling 44,100,000 shares, an increase of 20.3% from the August 15th total of 36,650,000 shares. Based on an average daily trading volume, of 5,420,000 shares, the short-interest ratio is currently 8.1 days. Currently, 8.6% of the company’s shares are short sold.

Several institutional investors and hedge funds have recently bought and sold shares of the stock. American International Group Inc. boosted its holdings in shares of Mylan by 0.3% in the 2nd quarter. American International Group Inc. now owns 176,140 shares of the company’s stock valued at $2,832,000 after purchasing an additional 603 shares during the last quarter. GWM Advisors LLC raised its holdings in shares of Mylan by 3.8% in the 2nd quarter. GWM Advisors LLC now owns 17,420 shares of the company’s stock worth $280,000 after purchasing an additional 643 shares during the period. Wesbanco Bank Inc. lifted its stake in shares of Mylan by 2.4% in the 1st quarter. Wesbanco Bank Inc. now owns 29,383 shares of the company’s stock valued at $438,000 after purchasing an additional 678 shares in the last quarter. CIBC Asset Management Inc grew its holdings in shares of Mylan by 3.0% during the 2nd quarter. CIBC Asset Management Inc now owns 24,955 shares of the company’s stock worth $401,000 after purchasing an additional 737 shares during the period. Finally, Cigna Investments Inc. New increased its position in Mylan by 6.3% during the 1st quarter. Cigna Investments Inc. New now owns 14,404 shares of the company’s stock worth $215,000 after purchasing an additional 850 shares in the last quarter. 88.18% of the stock is currently owned by institutional investors and hedge funds.

Shares of Mylan stock traded up $0.05 during trading on Wednesday, hitting $16.00. 389,526 shares of the stock were exchanged, compared to its average volume of 6,493,951. The company has a debt-to-equity ratio of 0.84, a current ratio of 0.93 and a quick ratio of 0.53. The firm’s 50-day moving average price is $16.08 and its 200 day moving average price is $16.06. The stock has a market cap of $8.25 billion, a price-to-earnings ratio of 30.21, a price-to-earnings-growth ratio of 2.05 and a beta of 1.50. Mylan has a 12-month low of $12.75 and a 12-month high of $23.11.

Mylan (NASDAQ:MYL) last posted its quarterly earnings results on Thursday, August 6th. The company reported $1.11 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.95 by $0.16. Mylan had a return on equity of 20.43% and a net margin of 2.35%. The company had revenue of $2.73 billion for the quarter, compared to analysts’ expectations of $2.74 billion. During the same period last year, the firm earned $1.03 earnings per share. Mylan’s quarterly revenue was down 4.2% on a year-over-year basis. As a group, research analysts forecast that Mylan will post 4.44 earnings per share for the current year.

Several equities analysts have weighed in on MYL shares. Raymond James reaffirmed a “buy” rating on shares of Mylan in a research report on Tuesday, September 8th. UBS Group lifted their price objective on shares of Mylan from $17.00 to $18.00 and gave the company a “neutral” rating in a report on Tuesday, August 11th. TheStreet raised shares of Mylan from a “d+” rating to a “c” rating in a research note on Thursday, August 6th. Finally, BidaskClub raised shares of Mylan from a “strong sell” rating to a “sell” rating in a research report on Tuesday. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $20.67.

About Mylan

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.

Recommended Story: Certificate of Deposit (CD) For Risk Adverse Investors?

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.